418 results on '"Pazgier, Marzena"'
Search Results
2. Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120
3. Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD
4. Three families of CD4-induced antibodies are associated with the capacity of plasma from people living with HIV to mediate ADCC in presence of CD4-mimetics
5. HIV-1 Vpu restricts Fc-mediated effector functions in vivo
6. VE607 stabilizes SARS-CoV-2 Spike in the “RBD-up” conformation and inhibits viral entry
7. Optimization of a Piperidine CD4-Mimetic Scaffold Sensitizing HIV‑1 Infected Cells to Antibody-Dependent Cellular Cytotoxicity.
8. Genetics of Exertional Heat Illness: Revealing New Associations and Expanding Heterogeneity.
9. Human Enteric α-Defensin 5 Promotes Shigella Infection by Enhancing Bacterial Adhesion and Invasion
10. Immune response profiles from humans experimentally exposed to Phlebotomus duboscqi bites
11. Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression
12. Structure and inhibition of SARS-CoV-2 spike refolding in membranes.
13. Defining genetic diversity of rhesus macaque Fcγ receptors with long-read RNA sequencing
14. Plasmatic HIV-1 soluble gp120 is associated with immune dysfunction and inflammation in ART-treated individuals with undetectable viremia
15. The structural basis for macaque Fc α receptor (CD89) activation by IgA Fc
16. Defining rules governing recognition and Fc-mediated effector functions to the HIV-1 co-receptor binding site
17. Piperidine CD4-Mimetic Compounds Expose Vulnerable Env Epitopes Sensitizing HIV-1-Infected Cells to ADCC
18. Structure-function Analyses Reveal Key Molecular Determinants of HIV-1 CRF01_AE Resistance to the Entry Inhibitor Temsavir
19. λ Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies
20. Characterization of a Novel CD4 Mimetic Compound YIR-821 against HIV-1 Clinical Isolates
21. Mouse α-Defensins: Structural and Functional Analysis of the 17 Cryptdin Isoforms Identified from a Single Jejunal Crypt
22. CD4 mimetics sensitize HIV-1-infected cells to ADCC
23. Temperature Influences the Interaction between SARS-CoV-2 Spike from Omicron Subvariants and Human ACE2
24. Decoding human-macaque interspecies differences in Fc-effector functions: The structural basis for CD16-dependent effector function in Rhesus macaques
25. The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11.
26. Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities
27. Bma-LAD-2, an Intestinal Cell Adhesion Protein, as a Potential Therapeutic Target for Lymphatic Filariasis
28. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding
29. Survivors Remorse: antibody‐mediated protection against HIV‐1
30. Human α-Defensin 6 Promotes Mucosal Innate Immunity Through Self-Assembled Peptide Nanonets
31. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19
32. D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms
33. Structural Basis for High-Affinity Peptide Inhibition of P53 Interactions with MDM2 and MDMX
34. HIV-1 Vpu restricts Fc-mediated effector functions in vivo
35. VE607 Stabilizes SARS-CoV-2 Spike In the “RBD-up” Conformation and Inhibits Viral Entry
36. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection
37. Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s
38. Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern
39. Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities
40. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological and pathological disease in a Syrian hamster model of COVID-19
41. Across Functional Boundaries: Making Nonneutralizing Antibodies To Neutralize HIV-1 and Mediate Fc-Mediated Effector Killing of Infected Cells
42. Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2
43. HIV-1 Envelope Glycoprotein Cell Surface Localization Is Associated with Antibody-Induced Internalization
44. Bma-LAD-2, an intestinal cell adhesion protein, as a potential therapeutic target for lymphatic filariasis
45. An anti-SARS-CoV-2 non-neutralizing antibody with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-hACE2 mice
46. Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy
47. Incorporating the Cluster A and V1V2 Targets into a Minimal Structural Unit of the HIV-1 Envelope to Elicit a Cross-Clade Response with Potent Fc-Effector Functions
48. Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer
49. Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells
50. Across functional boundaries: making non-neutralizing antibodies to neutralize HIV-1 and mediate Fc-mediated effector killing of infected cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.